Online inquiry

IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11013MR)

This product GTTS-WQ11013MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&CLEC12A gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000733.4; NM_001207010.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 160364
UniProt ID P07766; Q5QGZ9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11013MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9277MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-132
GTTS-WQ9216MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ7959MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ15458MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ15229MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TAK-079
GTTS-WQ2617MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ243MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ14807MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-70
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW